Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Andrade

Showing results (601-610 of 625) with videos related to

Pageof 63
Sort By:
Nature Communications|March 3, 2023
Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humansKodihalli C Ravindra, Vishal S Vaidya, Zhenyu Wang, et al.
Journal of Gastroenterology|April 15, 2024
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosisJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.
Diagnostic and Prognostic Research|September 12, 2023
Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case-control studyJane I Grove, Camilla Stephens, M Isabel Lucena, et al.
Journal of Proteome Research|February 28, 2012
Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progressionJ Barr, J Caballería, I Martínez-Arranz, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvirJuan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, et al.
Journal of Hepatology|May 18, 2016
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injuryInmaculada Medina-Caliz, Mercedes Robles-Diaz, Beatriz Garcia-Muñoz, et al.
The American Journal of Gastroenterology|June 23, 2021
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational StudyAnna Reig, Carmen Álvarez-Navascués, Mercedes Vergara, et al.
United European Gastroenterology Journal|June 19, 2024
Fibroblast growth factor 21 is a hepatokine involved in MASLD progressionRocío Gallego-Durán, Javier Ampuero, Douglas Maya-Miles, et al.
Gastroenterology|May 17, 2011
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II allelesM Isabel Lucena, Mariam Molokhia, Yufeng Shen, et al.
Ebiomedicine|March 25, 2026
Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injuryMaria J Monte, Thi Dong-Binh Tran, Jane I Grove, et al.
Pageof 63

Showing results (601-610 of 625) with videos related to

Sort By:
Pageof 63
Nature Communications|March 3, 2023
Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humansKodihalli C Ravindra, Vishal S Vaidya, Zhenyu Wang, et al.
Journal of Gastroenterology|April 15, 2024
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosisJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.
Diagnostic and Prognostic Research|September 12, 2023
Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case-control studyJane I Grove, Camilla Stephens, M Isabel Lucena, et al.
Journal of Proteome Research|February 28, 2012
Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progressionJ Barr, J Caballería, I Martínez-Arranz, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvirJuan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, et al.
Journal of Hepatology|May 18, 2016
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injuryInmaculada Medina-Caliz, Mercedes Robles-Diaz, Beatriz Garcia-Muñoz, et al.
The American Journal of Gastroenterology|June 23, 2021
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational StudyAnna Reig, Carmen Álvarez-Navascués, Mercedes Vergara, et al.
United European Gastroenterology Journal|June 19, 2024
Fibroblast growth factor 21 is a hepatokine involved in MASLD progressionRocío Gallego-Durán, Javier Ampuero, Douglas Maya-Miles, et al.
Gastroenterology|May 17, 2011
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II allelesM Isabel Lucena, Mariam Molokhia, Yufeng Shen, et al.
Ebiomedicine|March 25, 2026
Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injuryMaria J Monte, Thi Dong-Binh Tran, Jane I Grove, et al.
Pageof 63